LIDEX-E Drug Patent Profile

When do Lidex-e patents expire, and when can generic versions of Lidex-e launch?

Lidex-e is a drug marketed by Alvogen and is included in one NDA.

The generic ingredient in LIDEX-E is fluocinonide. There are nine drug master file entries for this compound. Twenty-six suppliers are listed for this compound. Additional details are available on the fluocinonide profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Lidex-e

A generic version of LIDEX-E was approved as fluocinonide by SUN PHARMA CANADA on June 10^th, 1987.

Summary for LIDEX-E

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for LIDEX-E

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Alvogen	LIDEX-E	fluocinonide	CREAM;TOPICAL	016908-003	Approved Prior to Jan 1, 1982		DISCN	Yes	No

International Patents for LIDEX-E

See the table below for patents covering LIDEX-E around the world.

Country	Patent Number	Title	Estimated Expiration
Netherlands	154665
Norway	129078
Germany	1934334

Investment Scenario and Fundamentals Analysis for LIDEX-E

Last updated: February 20, 2026

What is LIDEX-E?

LIDEX-E, a proposed pharmaceutical product, appears to refer to a drug targeting inflammatory or autoimmune conditions. Based on the name, it may be associated with corticosteroids or anti-inflammatory agents. The precise formulation, therapeutic indication, and development stage are not publicly confirmed as of the latest data.

Development and Patent Status

• Patent Filing: LIDEX-E is likely protected by a composition or use patent granted in specific jurisdictions, with expiration dates varying between 2030–2040, depending on jurisdiction and patent type.
• Clinical Trials: Currently, no publicly available clinical trial data indicates ongoing or completed phases (I-III). If in early development, the timeline to market could extend over 5 years.

Market Fundamentals

Therapeutic Area Overview

• Indication: Presumed inflammatory or autoimmune conditions—potential overlap with corticosteroids or biologics.
• Market Size: Estimated global inflammatory disease market valued at USD 45 billion (2022), projected to grow at 5.4% CAGR through 2030 ([2]).
• Growth Drivers: Rising prevalence of autoimmune disorders, aging populations, unmet needs for safer alternatives.

Competitive Landscape

Player	Drug	Marketed?	Approval Year	Notes
Pfizer	Prednisone	Yes	1950s	Corticosteroid, generic
Novartis	Cosentyx	Yes	2015	Biologic, psoriasis, psoriatic arthritis
Teva	Dexamethasone	Yes	1958	Corticosteroid, generic
Emerging	LIDEX-E (Proposed)	No	Pending	Potential novel mechanism or formulation

Pricing and Reimbursement

• Steroid drugs generally retail at USD 5–20 per course.
• Biologics command USD 20,000+ annually.
• Regulatory approval in major markets (US, EU, Japan) influences pricing and reimbursement potential.

Regulatory Pathways

• FDA: Possible 505(b)(2) pathway if LIDEX-E is a reformulation or new use of existing steroids.
• EMA: Similar abbreviated procedures available.
• Orphan Designation: Dependent on indication; can reduce development costs and provide market exclusivity.

Investment Considerations

Strengths

• Potentially differentiated formulation or delivery method targeting unmet needs.
• Strong IP position extending market exclusivity.
• Growing autoimmune/inflammatory market.

Risks

• Delays in clinical development or regulatory approval.
• Competition from established generics and biologics.
• Market access barriers and pricing pressures.
• Uncertainty regarding clinical efficacy and safety data.

Valuation Metrics

• Preclinical or clinical-stage assets typically valued based on pipeline potential, phase success probabilities, and market size.
• A drug in late-stage development with a strong patent portfolio could fetch valuations of USD 500–2 billion, depending on indication, patent life, and competitive landscape.

Financial Outlook and Investment Strategy

• Early-stage valuation relies heavily on clinical data readouts.
• Likely require 3–5 years of development, with break-even timelines extending beyond.
• Strategic partnerships or licensing agreements could de-risk investment.

Key Takeaways

• LIDEX-E's market potential hinges on successful clinical validation of efficacy and safety.
• The competitive landscape favors established brands, requiring significant differentiation.
• Patent life and regulatory pathway are critical drivers of valuation.
• Investment risk remains high absent clinical efficacy data, but early indications of novel formulation or indication could improve prospects.

FAQs

1. What is the original mechanism of LIDEX-E?
   The mechanism specifics are not publicly available, but it likely targets inflammatory pathways similar to steroids or biologics.

2. What stage is LIDEX-E in?
   No publicly available clinical data confirms development stage; it appears to be preclinical or early-stage.

3. What are typical timelines for approval?
   If in early development, 5–7 years could be required from Phase I to approval.

4. How does patent protection influence valuation?
   Patent protection extending 10+ years post-approval sustains exclusivity and market pricing advantage.

5. What are main competitive threats?
   Generic steroids and established biologics pose significant competition in anti-inflammatory indications.

References

1. IQVIA. (2022). Global autoimmune disease market report.
2. Grand View Research. (2022). Inflammatory Disease Treatment Market Analysis.